Bharat Biotech‘s COVID-19 vaccine Covaxin has shown an efficacy of 77.8% in phase 3 trial data approved by the Drugs Controller General of India’s (DCGI) Subject Expert Committee (SEC), ANI reported quoting sources on Tuesday. 

The data from the phase 3 trial was given to the DCGI over the weekend, and was approved in a SEC meeting today. 

Also Read | Delta plus COVID variant found in 3 states in India. What we know so far

The trial data is yet to be published in a peer-reviewed international medical journal. Bharat Biotech had earlier said publication will take nearly three months and can only happen after data has been submitted to the DCGI. 

The Hyderbad-based firm is currently supplying Covaxin at Rs 150 per dose to the Centre, Rs 400 to the state government and Rs 1,200 to private hospitals.

Also Read | All we know about Joe Biden’s plan of donating 55 million COVID vaccine doses

Initial analysis of the phase 3 trial data, which was released in March, showed the vaccine was 81% effective in preventing COVID-19 in people without prior infection after the second dose. The vaccine also reduced risk of hospitalisation by 100% in case of infection.